However, ORR of advanced GC patients toward anti-PD-1 mAb remains to be modest and exploring novel treatment strategies such as combinatorial therapies to overcome resistance to cancer immunotherapy are necessary to improve the ORR. Here, PDCD1 is linked to gastric cancer.